Chargement en cours...

吉非替尼可能通过EGFR启动子甲基化诱导肺腺癌细胞继发性耐药

BACKGROUND AND OBJECTIVE: Nowadays the secondary resistance of gefitinib in the treatment of lung adenocarcinoma is an outstanding problem. This research is to explore whether the gefitinib secondary resistance can be induced by gefitinib, to explore whether epidermal growth factor receptor (EGFR) p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Zhongguo Fei Ai Za Zhi
Format: Artigo
Langue:Inglês
Publié: 中国肺癌杂志编辑部 2015
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000283/
https://ncbi.nlm.nih.gov/pubmed/25936882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2015.04.04
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!